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CLBACKGROUND & AIMS: There is controversy over the ability
of transjugular intrahepatic portosystemic shunts (TIPS) to
increase survival times of patients with cirrhosis and refractory
ascites. The high rate of shunt dysfunction with the use of
uncovered stents counteracts the beneﬁts of TIPS. We
performed a randomized controlled trial to determine the
effects of TIPS with stents covered with polytetraﬂuoroethylene
in these patients. METHODS: We performed a prospective
study of 62 patients with cirrhosis and at least 2 large-volume
paracenteses within a period of at least 3 weeks; the study was
performed at 4 tertiary care centers in France from August
2005 through December 2012. Patients were randomly
assigned to groups that received covered TIPS (n ¼ 29) or
large-volume paracenteses and albumin as necessary (LVPþA,
n ¼ 33). All patients maintained a low-salt diet and were
examined at 1 month after the procedure then every 3 months
until 1 year. At each visit, liver disease–related complications,
treatment modiﬁcations, and clinical and biochemical variables
needed to calculate Child-Pugh and Model for End-Stage Liver
Disease scores were recorded. Doppler ultrasonography was
performed at the start of the study and then at 6 and 12 months
after the procedure. The primary study end point was survival
without a liver transplant for 1 year after the procedure.
RESULTS: A higher proportion of patients in the TIPS group
(93%) met the primary end point than in the LVPþA group
(52%) (P¼ .003). The total number of paracenteseswas 32 in the
TIPS group vs 320 in the LVPþA group. Higher proportions of
patients in the LVPþA group had portal hypertension-related
bleeding (18% vs 0%; P ¼ .01) or hernia-related complications
(18% vs 0%; P¼ .01) than in the TIPS group. Patients in LVPþA
group had twice as many days of hospitalization (35 days) as the
TIPS group (17 days) (P ¼ .04). The 1-year probability of
remaining free of encephalopathy was 65% for each group.
CONCLUSIONS: In a randomized trial, we found covered stents
for TIPS to increase the proportion of patients with cirrhosis
and recurrent ascites who survive transplantation-free for 1
year, compared with patients given repeated LVPþA. These
ﬁndings support TIPS as the ﬁrst-line intervention in such
patients. ClinicalTrials.gov ID: NCT00222014.© 2017 by the AGA Institute. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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Keywords: Liver Fibrosis; TIPS; Refractory Ascites; PHT.efractory or recurrent ascites is a severe complica-Rtion of cirrhosis, with a mean 1-year survival rate of
50%.1,2 Patients could beneﬁt from liver transplantation,
but <20% of them will receive transplants because of
contraindication or advanced age. Another therapeutic
option is repeated large-volume paracentesis with albumin
(LVPþA) infusion. However, the underlying liver disease is
not improved and clinical outcomes remain dismal.3,4 Portal
hypertension (PHT) is the main determinant of ascites, and
decreasing portal pressure by portosystemic shunt has been
shown to relieve ascites.5
Randomized controlled trials (RCT) on transjugular
intrahepatic portosystemic shunt (TIPS) vs LVP in patients
with refractory ascites showed an important reduction of
recurrence of tense ascites in patients allocated to TIPS.6–10
However, all of those studies were performed with uncov-
ered stents, leading to a high rate of shunt dysfunction,
which was the main drawback of this treatment.6–11
The development of polytetraﬂuoroethylene (PTFE)-
covered stents was considered major progress in this ﬁeld,
owing to a substantial decrease in the rate of shunt dysfunc-
tion and to an improvement in clinical outcomes.12–15
Furthermore, the selection of patients for TIPS has been
shown to be crucial in order to observe a potential gain in term
of survival.10 Actually, an improved 1-year survival rate was
demonstrated using covered stents in highly selected patients
with cirrhosis and variceal bleeding.16 We therefore hypoth-
esized that both accurate selection17 and the use of covered
stents should improve the prognosis for patients with
cirrhosis and recurrent ascites treated by TIPS.
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ascites aimed to compare the efﬁcacy of covered TIPS to
LVPþA in terms of liver transplantation-free survival (TFS).
Methods
Study Design
Between August 2005 and December 2012, patients with
cirrhosis and at least 2 LVPs within a minimum interval of 3
weeks were considered for inclusion.
Inclusion criteria were patients with cirrhosis, as docu-
mented by previous liver biopsy or a combination of usual
clinical and biochemical signs; age older than 18 years and
younger than 70 years; recurrent tense ascites; and signed
informed consent form.
Exclusion criteria were patients who had required >6 LVPs
within the previous 3 months; patients expected to receive
transplants within the next 6 months or on waiting list; usual
contraindications for TIPS, congestive heart failure, history or
presence of pulmonary hypertension, complete portal vein
thrombosis, recurrent overt hepatic encephalopathy (OHE),
hepatocarcinoma, severe liver failure (deﬁned by prothrombin
index <35% or total bilirubin >100 mmol/L or Child-Pugh
Score >12), serum creatinine >250 mmol/L, uncontrolled
sepsis, known allergy to albumin, pregnant or breastfeeding
women, refusal to participate, or patient unable to receive in-
formation or to sign written informed consent.
All patients provided written informed consent. The study
protocol was approved by the local ethics committee (CCPPRB
Toulouse II). Three centers were closed and replaced by 3
others because of noncompliance with good research practice
and guidelines (the patients included in those centers were not
analyzed) or no effective inclusion. Accordingly, the patients
considered for analysis were included in Toulouse, Paris, Lille,
and Angers.
The main end point was 1-year liver TFS. Secondary end
points were ascites recurrence and treatment failure as deﬁned
here, the rate of OHE, PHT-related complications, other
complications of cirrhosis, and the number of days in hospital
during a 1-year period after inclusion.
Treatment Procedures
Diagnostic evaluation before randomization included clinical
assessment of cirrhosis complications, usual blood tests, Doppler
ultrasonography of the abdomen, and echocardiography to rule
out exclusion criteria. After the investigator received written
informed consent, randomization was generated online by
computer, equilibrated for each center, stratiﬁed according to
whether cirrhosis was alcoholic or not and adjusted every
10 patients. TIPS was performed under sedation as described
previously.13 For homogeneity reasons, technical recommenda-
tions for TIPS placement were as follows: a 10-mm covered stent
was used (Viatorr; TIPS endoprosthesis, W.L. Gore & Associates,
Inc, Flagstaff, AZ), dilated to 8 or 10 mm Hg according to the
hemodynamic response. The aim was to reduce portal pressure
gradient (PPG) <12 mm Hg.
Follow-Up
All patients were maintained on a low-salt diet. Patients had
a clinical examination at 1 month and then every 3 months upto 1 year. At each visit, liver disease-related complications,
treatment modiﬁcations, and clinical and biochemical variables
needed to calculate Child-Pugh and Model for End-Stage Liver
Disease scores were recorded. Doppler ultrasonography was
performed at the beginning, and 6 and 12 months after.
Patients were followed for 1 year or until liver transplantation
or death.
Patients included in the LVPþA group were treated by
LVPþAwhenever required. Eight grams albumin per liter ascites
extracted were infused when >3 L ascitic ﬂuid had been
removed. The use of diuretics was allowed at the maximal
tolerated dose and compliance with low-sodium diet was
assessed by direct questioning and natriuresis. In the group
treated by LVPþA, failure was deﬁned as the need for >6 LVPs
within 3 months and alternative treatment, mainly TIPS or liver
transplantation could be proposed. All of these patients with
treatment failurewere to be followed up to 1 year after inclusion.
In the TIPS group, the relapse of ascites requiring at least 2 LVPs
or its persistence after 2 months were considered as failure.
When shunt dysfunction was suspected because of relapse of
ascites or incomplete response 2 months after the procedure, an
angiography with a PPG measurement was performed. If shunt
dysfunction was conﬁrmed, angioplasty or PTFE re-stenting
aiming to reduce PPG <12 mm Hg were performed.Statistical Analyses
The initial sample calculation, based on available published
data in 2004, was 60 patients per group. During the course of the
study, a 52% 1-year TFS among patients treated by LVPþA
infusion was reported by a meta-analysis18 and 2 studies9,10
found an 80% 1-year TFS survival rate in patients treated by
TIPS with uncovered stents. Accordingly, the number of patients
needed for our study was recalculated based on the following
updated hypotheses: 1-year TFS rate of 85% among patients
treated with PTFE-covered stent and 52% among those treated
by LVPþA. To detect such a difference, a minimum of 30 patients
per groupwas needed (2-sided test, a¼ .05 and b¼ .2), adjusted
for a 5% loss of follow-up.
The SPSS statistical package (SPSS Inc, Chicago, IL) was used
for the analysis according to an intention to treat strategy.
Comparisons between the 2 groups were performed using
Student t test or c2 test, as required. Actuarial probability curves
were constructed using the Kaplan–Meiermethod and compared
with the log-rank test. Patients in the LVPþA group who were
switched to TIPS treatmentwere censored alive at the time of the
shunt procedure for the TFS analysis. Cox regression analysis
was used to identify independent predictors for the primary end
point. Statistical signiﬁcance was established at P < .05.
All authors had access to the study data and reviewed and
approved the ﬁnal manuscript.Results
Patients’ Characteristics
Among the 137 patients admitted for recurrent ascites
during the study period, 62 patients were included. Reasons
for excluding the other 75 patients are listed in
Supplementary Figure 1. Of the 62 included patients, 29
were enrolled in the TIPS group and 33 in the LVPþA group.
The baseline characteristics of the patients were similar in
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29 patients, with a decrease of mean PPG from 15.4 ± 4.6
mm Hg to 6.4 ± 4.2 mm Hg (P < .001). A value of PPG <12
mm Hg was achieved in all patients. No severe related
procedure complications were reported in the 2 groups.
Median follow-up of the whole cohort was 365 days (range,
31–483 days).LI
VE
RTransplantation-Free Survival
One patient in each group was lost to follow-up 274 and
284 days after inclusion. Two patients died in the TIPS
group 35 and 205 days after the procedure and none
received transplants. In the LVPþA group, 4 patients
received transplants at a mean delay of 257 ± 60 days, and
5 died at a mean delay of 188 ± 107 days after inclusion.
Reasons for liver transplantation and causes of death areTable 1.Baseline Characteristics of the 62 Patients
According to Assigned Treatment
Characteristic
TIPS
(n ¼ 29)
LVPþA
(n ¼ 33) P value
Sex, male/female, n 17/12 27/6 .06
Age, y 56.7 ± 5.7 56.4 ± 7.9 .868
Weight, kg 67 ± 13 72 ± 13 .132
BMI, kg/m 23.6 ± 4.3 24.3 ± 3.3 .465
Etiology, %
Alcohol 90 85 1.00
Stopped alcohol use 70 80 1.00
Chronic hepatitis C 3 9 .616
Other 7 6 1.00
History of SBP, % 7 15 .432
History of OHE, % 0 3 1.00
History of variceal bleeding, % 28 30 1.00
History of renal failure, % 21 18 1.00
No. of paracentesis, last 3 mo 4.5 ± 1.4 4.2 ± 1.3 .377
Duration of cirrhosis, y 3.7 ± 4.1 2.9 ± 3.4 .364
Trail making test A, s 71 ± 33 66 ± 44 .614
Bilirubin, mmol/L 17.8 ± 12.7 17.5 ± 16.4 .938
INR 1.39 ± 0.27 1.46 ± 0.30 .382
Albumin, g/L 30.7 ± 5.5 33.4 ± 5.4 .06
Serum creatinine, mmol/L 84.6 ± 30.1 85.6 ± 21.4 .888
Serum sodium, mmol/L 134 ± 4 132 ± 4 .06
Hemoglobin, g/dL 11.5 ± 1.7 11.8 ± 1.7 .543
Platelets, 103/mm3 179 ± 94 169 ± 90 .687
ASAT, UL/N 1.69 ± 0.79 1.63 ± 0.85 .771
ALAT, UL/N 1.09 ± 0.28 1.12 ± 0.38 .711
Child-Pugh score 9.1 ± 1.4 9.0 ± 1.6 .922
Child-Pugh class: B/C, n 19/10 22/11 1.00
MELD score 12.1 ± 3.5 13.1 ± 3.9 .289
Diuretics used
Furosemide, mg/d 68 ± 67 58 ± 24 .474
Aldosterone antagonist,mg/d 109 ± 58 120 ± 56 .580
b-blockers, % 45 48 .804
Antibiotic prophylaxis, % 10 15 .713
Follow-up, d 350 ± 99 314 ± 93 .144
NOTE. Values are mean ± SD unless otherwise noted.
ALAT, alanine aminotransferase; ASAT, aspartate amino-
transferase; BMI, body mass index; INR, international
normalized ratio; MELD, Model for End-Stage Liver Disease;
SBP, spontaneous bacterial peritonitis.
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TFS was greater in the TIPS group than in the LVPþA group:
93% (95% conﬁdence interval, 82%–100%) and 52% (95%
conﬁdence interval, 34%–60%), respectively (P ¼ .003)
(Figure 1).
Univariate analysis showed that a low international
normalized ratio, low serum bilirubin, high serum sodium at
baseline and assignment to TIPS group were associated with
a higher 1-year TFS. The multivariate analysis using Cox
model, including age and the 4 variables mentioned, showed
that only the allocation to the TIPS group was associated
with 1-year TFS (hazard ratio, 2.1; 95% CI, 1.1–4.0)
(Table 2).
Recurrence of Ascites and Failure of Treatment
During the 1-year follow-up, the total number of para-
centeses was 32 (1.0 ± 1.6 per patient) in the TIPS group
and 320 in the LVPþA group (10.1 ± 7.0 per patient)
(P < .001). Fifteen patients from the TIPS group did not
require further paracentesis during follow-up compared
with none in the LVPþA group (P < .05). Total volume
extracted and total albumin infusion were 169 L and 1170 g,
respectively, in the TIPS group compared with 2061 L and
17,727 g in the LVPþA group (P < .001) (Table 3). Pressure
gradient was not different before or after TIPS between
patients who experienced failure and those who did not
(respectively 15.6 ± 4.1 mm Hg vs 18.7 ± 3.8 mm Hg before
and 5.5 ± 2.4 mm Hg vs 6.7 ± 0.6 mm Hg after).
In the LVPþA group, 15 patients were treated by TIPS
during follow-up, 14 because they needed >6 LVPs within 3
months (according to the planned protocol) and 1 because
of associated recurrent variceal bleeding. In the TIPS group,
1 patient developed an early thrombosis of the shunt,
resulting in persistence of ascites after the procedure and
was treated successfully by insertion of a second stent. As a
whole, the probability of being free of treatment failure, as
deﬁned in Methods, was signiﬁcantly greater in the TIPS
group (89% vs 29% in the LVPþA group; P < .001;
Supplementary Figure 2).
Hepatic Encephalopathy and Other Liver-Related
Complications
The 1-year probability of remaining free of OHE was
65% in both groups (Supplementary Figure 3). No differ-
ence was observed when considering only patients with
episodes of OHE grade >2 or the number of episodes per
patient (Table 3). One patient in TIPS group required stent
reduction because of severe recurrent OHE.
The rates of PHT-related bleeding and hernia-related
complications were signiﬁcantly greater in the LVPþA
group, while spontaneous bacterial peritonitis, hepatorenal
syndrome, infection, and hepatocellular carcinoma were
found to be as frequent in both groups (Table 3). The number
of days in hospital was doubled in the LVPþA group
compared with the TIPS group (35 ± 40 vs 17 ± 28, P¼ .04).
The comparison between liver and renal function tests
throughout a 6-month follow-up period showed that albu-
min, Child-Pugh score, creatinine, and serum sodium
Figure 1. Probability of
survival without liver
transplantation in patients
allocated to covered TIPS
group and in those allo-
cated to LVPþA group.
160 Bureau et al Gastroenterology Vol. 152, No. 1
CLINICAL
LIVERimproved in the TIPS group only, while international
normalized ratio and bilirubin did not change signiﬁcantly
in the 2 study arms (Table 4). Furthermore, both plasma
renin activity and aldosterone concentration decreased in
the TIPS group only during the same period (Table 4).
Plasma renin activity was negatively correlated with systolic
blood pressure (r ¼ 0.384; P < .05) and blood pressure at
3 and 6 months was found to be greater in TIPS group
compared with LVPþA group: 136 ± 19 mm Hg vs 116 ± 12
mm Hg, respectively; P < .002 (see Supplementary Table 2).
At 3 months, heart rate was also found to be higher in TIPS
group as compared with LVP group (85 ± 12 beats/min vs
73 ± 15 beats/min; P ¼ .03).Discussion
The present study showed that 1-year TFS of selected
patients with cirrhosis and recurrent ascites was
improved by using TIPS with covered stents as comparedTable 2.Prognostic Parameters Associated With Survival Withou
Parameter
Patients alive
without LT (n ¼ 11)
Pa
INR, mean ± SD 1.4 ± 0.3
Serum sodium, mmol/L mean ± SD 129 ± 3
Bilirubin, mmol/L mean ± SD 27 ± 21
TIPS/paracentesis, % 93/73
HR, hazard ratio; INR, international normalized ratio; LT, liver trwith paracentesis and albumin infusion. Treatment with
TIPS was also associated with a decreased risk of other
PHT-related complications and less hospitalizations. The
risk of hepatic encephalopathy was similar in both
groups.
In patients with tense ascites, although the beneﬁt of
TIPS in terms of recurrence has been established, the impact
on survival remains controversial. RCTs and review meta-
analyses did not observe any signiﬁcant difference in
survival between patients allocated to TIPS and those
allocated to LVP. For that reason, the experts of the Inter-
national ascites club stated that repeated paracenteses is the
ﬁrst-line treatment and TIPS should be considered in
patients with very frequent requirement of LVP.3 However,
those studies, all performed with bare stents, did not take
into account the confounding effect of liver transplantation
on survival, which could constitute an important bias. A
meta-analysis of individual data taking into account the
competitive risk of being transplanted during the follow-upt Liver Transplantation in Univariate and Multivariate Analyses
tients dead or received
transplant (n ¼ 51)
Univariate
P value
Multivariate HR
(95% CI); P value
1.5 ± 0.2 .09 0.8 (0.3–2.3); NS
134 ± 4 .001 0.9 (0.9–1.0); NS
15 ± 12 .05 1.0 (1.0–1.0); NS
7/27 .048 2.0 (1.1–4.0); .03
ansplantation.
Table 3.Clinical Outcomes in Patients According to
Treatment Group
Outcome
TIPS
(n ¼ 29)
LVPþA
(n ¼ 33)
No. of paracenteses per patient, mean ± SD 1 ± 1 10 ± 7***
Volume extracted, L/patient, mean ± SD 6 ± 10 64 ± 47***
Albumin infusion, g/patient, mean ± SD 39 ± 70 550 ± 458***
Days in hospital, mean ± SD 17 ± 28 35 ± 40*
Patients with OHE, n 10 11
Episodes of OHE per patient, n, mean ± SD 1.6 ± 0.7 1.7 ± 0.8
Patients with OHE grade >2, n 4 7
Patients with PHT-related bleeding, n 0 6**
Patients with hernia-related complication, n 0 6**
Patients with HRS, n 0 1
Patients with SBP, n 0 2
Patients with sepsis, n 5 9
HCC, n 0 1
HCC, hepatocellular carcinoma; HRS, hepatorenal syndrome;
SBP, spontaneous bacterial peritonitis.
*P < .05; **P < .01; ***P < .001.
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However, such a demonstration needs to be conﬁrmed in
the context of an RCT with a relevant study design takingTable 4.Evolution of Hepatic and Renal Functions Between
Baseline and Month 6 According to the Group
Variable Baseline Month 6
Bilirubin, mmol/L
TIPS 20.8 ± 14.4 21.5 ± 19.5
LVPþA 15.8 ± 12.1 17.4 ± 14.8
Albumin, g/L
TIPS 31.2 ± 4.7 34.0 ± 5.6**
LVPþA 33.3 ± 4.8 32.2 ± 6.2
INR
TIPS 1.38 ± 0.27 1.35 ± 0.22
LVPþA 1.52 ± 0.31 1.48 ± 0.29
Creatinine, mmol/L
TIPS 86.1 ± 31.2 70.3 ± 27.3**
LVPþA 84.6 ± 23.7 81.6 ± 20.1
Serum sodium, mmol/L
TIPS 135 ± 5 139 ± 2**
LVPþA 132 ± 5 133 ± 5
Child-Pugh score
TIPS 9.0 ± 1.4 7.0 ± 1.7**
LVPþA 9.2 ± 1.8 8.6 ± 2.1
MELD score
TIPS 12.3 ± 3.4 13.1 ± 5.9
LVPþA 14.2 ± 3.6 13.6 ± 4.3
Plasma renin activity, mU/mL
TIPS 860 ± 1329 59 ± 46*
LVPþA 856 ± 1338 1046 ± 1993
Plasma aldosterone, ƞg/L
TIPS 325 ± 554 32 ± 54*
LVPþA 214 ± 201 294 ± 323
NOTE. In the LVPþA group, the values for patients treated by
TIPS before month 6 were those measured just before the
crossover for the TIPS procedure.
*P< .05 vsbaseline;**P< .01 vsbaseline;***P< .001vsbaseline.into account the survival impact of liver transplantation. The
accuracy of the selection process to consider a patient with
recurrent ascites as a candidate for TIPS is also crucial to
reduce potential biases related to the presence of
confounding factors that could interfere in the evaluation of
the impact of TIPS on survival. These considerations are the
strength of the present work with the use of covered stents.
Actually, we and others already reported that the use of
covered stents improves clinical outcomes.13,14 In addition,
we found that an accurate selection of patients improves
survival.17 As a result, the prognosis of patients with a high-
risk variceal bleeding has been improved.16 Consequently,
the same concept was applied, in the present study, to
patients with recurrent ascites. The rate of 1-year TFS was
93% in the TIPS group, which is markedly better than rates
reported previously (80% in the 2 more recent studies9,10).
This could be related to greater experience with the TIPS
procedure: no technical failure occurred in the present
study, while the rate of failures reached 6% to 23% in the
previous 5 studies. An optimized selection (most patients
were Child B without prior encephalopathy and younger
that 65 years) might have also contributed to these results,
however, TFS in the paracentesis group was similar to
that observed in most studies (52% in a previous
meta-analysis18). Therefore, we believe that the use of
covered stents was the main determinant of the observed
improvement in outcomes. The rate of shunt dysfunction
was close to 80% at 1 year in most previous studies, owing
to a recurrence of PHT-related complications in >50% of
patients randomized in the TIPS group.6–11 Therefore, TIPS
with uncovered stent should not be considered effective or
recommended any longer for the long-term treatment of
PHT. An improvement of general health and nutritional
status could also have played a role, but this issue remains
to be investigated.19–21 Finally, plasma renin activity, a
well-known prognostic parameter in patients with
cirrhosis,22 dramatically decreased after TIPS. This is a
hallmark of hemodynamic changes after TIPS. This last
consequence was probably the main beneﬁcial effect of
permanent shunting, owing to an enduring improvement of
hemodynamic conditions that could have contributed to a
better clinical outcome. Because it has been reported that
b-blockers could worsen prognosis in patients with chronic
ascites,23,24 assessing the effects of b-blocker discontinua-
tion in patients treated by TIPS deserves additional inves-
tigation. Stopping alcohol use could also have contributed to
an improvement in liver functions, but it is noteworthy that
abstinence was reported to be as frequent in both groups
and the need for repeated paracenteses increased in most
patients of the LVPþA group.
As already reported for variceal bleeding, a careful
selection of patients restricts the number of potential
candidates for TIPS. In previous RCTs, patients included
represented 20% to 50% of screened patients compared
with 45% in the present study. Accordingly, other strategies
in non-candidates require additional studies: liver trans-
plantation in patients with refractory ascites and high Model
for End-Stage Liver Disease score, or new procedures still
under investigation.23,25
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observed. In the absence of a double-blind assessment, this
must be considered with caution. However, this is in
agreement with our previous observation showing that the
use of covered stents did not increase this risk of OHE
compared with bare stents,13,14 probably by preventing
events at risk of precipitating encephalopathy, such as
variceal bleeding, ascites, use of diuretics, hospitalizations,
and shunt revisions.
No difference was observed among centers or according
to etiology of the liver disease, however, these results must
be also interpreted with caution, as all other prognostic
parameters, because of the small sample size. In addition, as
most patients had alcoholic liver disease, no deﬁnitive
conclusion can be drawn for patients with other chronic
liver diseases. Finally, the results on survival could be rather
different in patients with other characteristics than those of
patients ﬁnally enrolled in the present study because
assessment of cirrhosis severity is sometimes difﬁcult in the
context of refractory ascites.
In conclusion, TIPS with covered stents improved 1-year
TFS in selected patients with recurrent ascites and should
therefore be preferred to LVP with volume expansion.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
j.gastro.2016.09.016.References
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